Literature DB >> 12622785

Evidence for an autoimmune pathogenesis of vitiligo.

Katia Ongenae1, Nanny Van Geel, Jean-Marie Naeyaert.   

Abstract

Vitiligo is a depigmenting disorder characterized by the development of white patches in various distributions, which are due to the loss of melanocytes from the epidermis. A variety of arguments from clinical observations to research findings in human and animal models support the hypothesis of autoimmunity and are reviewed in this article. The association with autoimmune diseases and organ-specific autoantibodies is well known. Various effective treatment options have an immunosuppressive effect. Today the autoimmune pathogenesis of the disease has become a rapidly evolving field of research. Detection of circulating melanocyte antibodies in human and animal models implicates a possible role of humoral immunity. Histological and immunohistochemical studies in perilesional skin suggest the involvement of cellular immunity in vitiligo. Recently, T-cell analyses in peripheral blood further support this hypothesis. Interestingly, new insights in the association of vitiligo and melanoma may help to clarify the role of autoimmunity in the development of vitiligo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12622785     DOI: 10.1034/j.1600-0749.2003.00023.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  74 in total

Review 1.  Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease.

Authors:  Richard A Spritz
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

2.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

3.  Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.

Authors:  Li Zhou; Kai Li; Yu-Ling Shi; Iltefat Hamzavi; Tian-Wen Gao; Marsha Henderson; Richard H Huggins; Oma Agbai; Bassel Mahmoud; Xiaofan Mi; Henry W Lim; Qing-Sheng Mi
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-12       Impact factor: 4.693

4.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

5.  A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families.

Authors:  Jian-Jun Chen; Wei Huang; Jin-Ping Gui; Sen Yang; Fu-Sheng Zhou; Quan-Geng Xiong; Hong-Bo Wu; Yong Cui; Min Gao; Wei Li; Jin-Xian Li; Kai-Lin Yan; Wen-Tao Yuan; Shi-Jie Xu; Jian-Jun Liu; Xue-Jun Zhang
Journal:  Am J Hum Genet       Date:  2005-04-04       Impact factor: 11.025

Review 6.  [Vitiligo. Diagnosis, differential diagnosis, and current patient management].

Authors:  A Hartmann
Journal:  Hautarzt       Date:  2009-06       Impact factor: 0.751

7.  Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.

Authors:  Mehmet Agirbasli; Mesut Eren; Songul Yasar; Kenan Delil; Fatih Goktay; Ebru Toksoy Oner; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

8.  Influence of Pregnancy on Vitiligo Activity.

Authors:  Kirsten C Webb; Sarah Lyon; Beatrice Nardone; Dennis P West; Roopal V Kundu
Journal:  J Clin Aesthet Dermatol       Date:  2016-12-01

9.  No Association between Vitiligo and Obesity: A Case-Control Study.

Authors:  Federica Dragoni; Rossana Conti; Simone Cazzaniga; Roberta Colucci; Lisa Pisaneschi; Luigi Naldi; Silvia Moretti
Journal:  Med Princ Pract       Date:  2017-09-12       Impact factor: 1.927

10.  Thyroid dysfunction and thyroid antibodies in Iranian patients with vitiligo.

Authors:  Moradi Sedighe; Ghafarpoor Gholamhossein
Journal:  Indian J Dermatol       Date:  2008-01       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.